BRITISH drug manufacturer AstraZeneca has withdrawn its application to hold clinical trials for its vaccine in the Philippines, according to the Food and Drug Administration (FDA).
It comes after the drug maker accepted a proposal from Russia’s Gamaleya Research Institute to begin clinical trials of its AZD1222 vaccine alongside Sputnik V to study its efficacy since both use adenovirus vectors that contain the genetic material of the SARS-CoV2 virus spike protein.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.